Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Xenon gas inhalation as a novel treatment for opioid withdrawal syndrome

Award Number: R41DA061962
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/01/2025
PERIOD OF PERFORMANCE END DATE: 07/31/2026

Group Awards By:

View Award Description

Xenon gas inhalation as a novel treatment for opioid withdrawal syndrome - ABSTRACT Opioid withdrawal symptoms (OWS) are highly aversive and occur in people with opioid use disorder (OUD) when their blood opioid levels wane, thereby increasing sympathetic nervous system (SNS) activity, a driver of OWS. OWS drive people to seek out and take opioids, including unprescribed opioids contaminated with fentanyl, leading to overdoses and tens of thousands of deaths per year. Managing OWS is considered a “gateway to opioid dependence treatment” and the “safest and most practical approach” for treating OUD. Xenon gas (Xe), which is used in humans at high concentration as an inhaled anesthetic and at lower concentrations as an inhaled imaging agent, inhibits SNS activity. Xe has no appreciable addiction liability and at subsedative doses induces few side effects in humans. Therefore, Xe has good potential for development as a novel treatment for OWS. McLean Hospital researchers recently reported in morphine-dependent mice that brief (10-min) exposure to inhaled 20% Xe inhibits naltrexone-precipitated OWS. General Biophysics, LLC is developing inhaled Xe treatment to inhibit inflammation leading to dementia. In this new Phase 1 STTR program, we seek to partner with McLean Hospital, which holds intellectual property covering the use of Xe to treat OUD (US 9,737,562 B2; EU 2931291 B1), and with Brigham Women’s Hospital, with who we have been collaborating on our dementia program, to develop inhaled Xe for blunting OWS. In addition to administrative activities, including holding a pre-IND meeting with FDA and designing the future clinical trial, we will propose target engagement studies to demonstrate attenuation of OWS according to the following specific aims: Aim 1: Using banked frozen brain tissues harvested from morphine-dependent mice in our prior study of Xe effects on naltrexone-precipitated opioid withdrawal symptoms, analyze effects of in vivo Xe inhalation on GSK3b protein expression and on MCP-1, IL-6, and IL-10 mRNA expression. Aim 2: Investigate effect of in vivo Xe inhalation on of GSK3b signaling in blood monocytes from healthy adults. Aim 3: In blood samples from patients with OUD experiencing OWS during medical opioid tapering, determine whether in vitro Xe exposures suppress inflammatory monocytes. This information will be used in designing the clinical trial to be submitted for Phase II STTR grant application. If Xe is effective, it could help reduce morbidity and mortality among the many people with OUD who do not benefit from existing treatments that target OWS. We look forward to submitting our application and we thank you very much for designing this Funding Opportunity.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	GENERAL BIOPHYSICS LLC	13 RIDGEFIELD RD	WAYLAND	MA	01778	MIDDLESEX	USA	Drug Use and Addiction Research Programs	001	1	12/12/2025	NEW	$0
2026	2025	GENERAL BIOPHYSICS LLC	13 RIDGEFIELD RD	WAYLAND	MA	01778	MIDDLESEX	USA	Drug Use and Addiction Research Programs	000	1	11/24/2025	NEW	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $400,000 )
2025	2025	GENERAL BIOPHYSICS LLC	13 RIDGEFIELD RD	WAYLAND	MA	01778	MIDDLESEX	USA	Drug Use and Addiction Research Programs	000	1	1/22/2025	NEW	$400,000
														Subtotal = $400,000

Grand Total All Awards = $400,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Xenon gas inhalation as a novel treatment for opioid withdrawal syndrome

Award Number: R41DA061962

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/01/2025

PERIOD OF PERFORMANCE END DATE: 07/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer